Horizon Therapeutics

FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
Motley Fool
FTC
M&A
Amgen
Horizon Therapeutics
Pfizer
Seagen
Flag link:
Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it
Horizon Therapeutics says Amgen deal could close earlier than planned if FTC fails to block it
CNBC
Horizon Therapeutics
M&A
Amgen
FTC
Flag link:
Few signs of gout pipeline flaring up
Few signs of gout pipeline flaring up
EP Vantage
gout
Selecta Biosciences
Sobi
SEL-212
3SBio
Amgen
Arthrosi Therapeutics
Atom Bioscience
Dyve Biosciences
Hinova Pharmaceuticals
Horizon Therapeutics
InventisBio
Jiangsu Hengrui Pharmaceuticals
JW Group
LG Chem
Olatec Therapeutics
Shanton Bioscience
Flag link:
Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal
Regeneron CEO backs FTC’s attempt to block $28B Amgen-Horizon deal
Medical Marketing and Media
Amgen
Horizon Therapeutics
FTC
Regeneron
antitrust
M&A
Leonard Schleifer
Flag link:
Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say
Does FTC attempt to block Amgen's Horizon buy spell trouble for Pfizer-Seagen? Not necessarily, analysts say
Fierce Pharma
FTC
M&A
Amgen
Horizon Therapeutics
Pfizer
Seagen
antitrust
Flag link:
Heightened US antitrust fears rattle biopharma
Heightened US antitrust fears rattle biopharma
EP Vantage
M&A
antitrust
Amgen
Astellas
Bellus Health
Globus Medical
GSK
Horizon Therapeutics
Merck
NuVasive
Pfizer
Prometheus Biosciences
Seagen
Flag link:
Amgen ‘Remains Committed’ to $27.8B Horizon Acquisition After FTC Challenge
Amgen ‘Remains Committed’ to $27.8B Horizon Acquisition After FTC Challenge
BioSpace
Amgen
Horizon Therapeutics
M&A
FTC
Flag link:
FTC sues to block Amgen’s $27.8B deal for Horizon Therapeutics
FTC sues to block Amgen’s $27.8B deal for Horizon Therapeutics
Medical Marketing and Media
Amgen
Horizon Therapeutics
FTC
M&A
Flag link:
A blockbuster year could be building
A blockbuster year could be building
EP Vantage
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Daiichi Sankyo
Eli Lilly
Gilead Sciences
Horizon Therapeutics
Merck
Moderna Therapeutics
Novartis
Novo Nordisk
Pfizer
Regeneron
Roche
Sanofi
Flag link:
As Amgen's revenues slide, so too do sales at its big buyout target Horizon
As Amgen's revenues slide, so too do sales at its big buyout target Horizon
Fierce Pharma
Amgen
earnings
Horizon Therapeutics
Flag link:
Viridian aims to prove itself in thyroid eye
Viridian aims to prove itself in thyroid eye
EP Vantage
Viridian Therapeutics
thyroid eye disease
Horizon Therapeutics
Tepezza
VRDN-001
Flag link:
Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study
Horizon's (HZNP) Tepezza Meets Goals in TED Expanded Use Study
Zacks.com
Horizon Therapeutics
Tepezza
clinical trials
thyroid eye disease
Flag link:
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon
Selecta, Sobi rout gout in pair of phase 3 trials that could challenge Horizon
Fierce Biotech
Sobi
Selecta Biosciences
gout
SEL-212
Horizon Therapeutics
Krystexxa
Flag link:
Amgen bond offering to help fund Horizon Therapeutics acquisition
Amgen bond offering to help fund Horizon Therapeutics acquisition
Seeking Alpha
Amgen
bond
M&A
Horizon Therapeutics
Flag link:
Warren keeps pressure on pharma, this time targeting Amgen and Indivior buyouts
Warren keeps pressure on pharma, this time targeting Amgen and Indivior buyouts
Fierce Pharma
Elizabeth Warren
Senate
FTC
M&A
Amgen
Horizon Therapeutics
Indivior
Opiant Pharmaceuticals
Flag link:
Horizon Bags Second Phase II Win in Sjögren’s Syndrome
Horizon Bags Second Phase II Win in Sjögren’s Syndrome
BioSpace
Horizon Therapeutics
Sjögren’s syndrome
clinical trials
dazodalibep
Flag link:
Biopharma's stock market winners of 2022 revealed
Biopharma's stock market winners of 2022 revealed
EP Vantage
pharma stocks
Merck
Eli Lilly
AbbVie
Daiichi Sankyo
Vertex Pharmaceuticals
Takeda
Sarepta Therapeutics
Halozyme
Horizon Therapeutics
Flag link:
JPM23: J&J stayed in the back seat during Horizon bidding war, CEO says
JPM23: J&J stayed in the back seat during Horizon bidding war, CEO says
Fierce Pharma
JNJ
Horizon Therapeutics
M&A
Flag link:
Horizon enrolls first subject in Phase II trial of antibody for DLE treatment
Horizon enrolls first subject in Phase II trial of antibody for DLE treatment
Clinical Trials Arena
Horizon Therapeutics
clinical trials
daxdilimab
DLE
discoid lupus
Flag link:
Billionaire John Paulson Stands To Make $500 Million From Horizon’s Sale To Amgen
Billionaire John Paulson Stands To Make $500 Million From Horizon’s Sale To Amgen
Forbes
Amgen
M&A
Horizon Therapeutics
John Paulson
Flag link:

Pages